BIOR - Biora submits updated IND application to FDA for BT-600
2023-10-30 17:37:32 ET
More on Biora Therapeutics
- Biora Therapeutics, Inc. (BIOR) Q2 2023 Earnings Call Transcript
- Biora IND for BT-600 delayed due to FDA request for more info
- Biora Therapeutics reduces debt by $50M, largest shareholder increases equity exposure
- Seeking Alpha’s Quant Rating on Biora Therapeutics
- Historical earnings data for Biora Therapeutics
For further details see:
Biora submits updated IND application to FDA for BT-600